Merck eyes growth beyond Keytruda with PAH drug Winrevair, aiming to offset the looming loss of exclusivity in 2028.

Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential ...

Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other ...

One of the biggest patent cliffs is set to hit the pharmaceutical industry this decade, with major players bracing for a blow ...

Second, SoFi could grow its revenue even without expanding its membership base, by cross-selling additional products to its ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers.

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Serendipity Space, a pioneering space-tech company developing microgravity-based pharmaceutical manufacturing solutions, has raised its pre-seed round from Campus Fund. The investment will accelerate ...